2-{[4-(Pyrimidin-2-yl)Piperazin-1-yl]methyl }-4-Oxo[4H]-1-Benzopyran

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2-{[4-(Pyrimidin-2-yl)Piperazin-1-yl]methyl }-4-Oxo[4H]-1-Benzopyran
• 英文别名: 2-[(4-Pyrimidin-2-ylpiperazin-1-yl)methyl]chromen-4-one
• 化学式: C₁₈H₁₈N₄O₂
• 分子量: 322.367
• InChiKey: PSBUPDBRPCHGGX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  58.6
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-(chloromethyl)-4H-chromen-4-one 、 1-(2-嘧啶基)哌嗪 在 potassium carbonate 作用下， 以 四氢呋喃 为溶剂， 以15%的产率得到2-{[4-(Pyrimidin-2-yl)Piperazin-1-yl]methyl }-4-Oxo[4H]-1-Benzopyran
  参考文献：
  名称：

  Synthesis and structure-activity relationships of novel 2-amino alkyl chromones and related derivatives as a site-selective ligands

  摘要：

  Starling from a random screening showing that 2-[(4-benzylpiperazinyl)methyl] chromone was a selective and potent sigma ligand, a series of analogues were synthesized. Introduction of a substituent on the chromone moiety, replacement of methylenes by carbonyl groups and benzyl by aryl groups decrease the affinity for sigma sites. The result obtained after introduction of various substituents on the aromatic part of the benzyl is strictly depending on the size and on the position of these substituents. Stretching of the carbon chain between the phenyl and the piperazine does not strongly modify the affinity. 2-[4-(4'-methoxy benzyl)-1-piperazinyl methyl] chromone has been tested in behavioral tests that permit to believe that such derivatives could be interesting for the treatment of psychosis. (C) Elsevier, Paris.

  DOI：

  10.1016/s0223-5234(98)80001-9

文献信息

• Heterocyclic Compounds And Uses Thereof In The Treatment Of Sexual Disorders
  申请人：Tworowski Dmitry

  公开号：US20100029671A1

  公开（公告）日：2010-02-04

  Novel heterocyclic compounds, which exhibit a dopamine receptor (preferably a D4 receptor) agonistic activity, and/or a PDE5 inhibitory activity, processes of preparing same, pharmaceutical compositions containing same and uses thereof in the treatment of sexual disorders such as decreased libido, orgasm disorder and erectile dysfunction are disclosed.

  本发明揭示了一种新型杂环化合物，其表现出多巴胺受体（优选为D4受体）激动活性和/或PDE5抑制活性，以及制备该化合物的方法，含有该化合物的药物组合物以及将其用于治疗性功能障碍，如性欲减退、性高潮障碍和勃起功能障碍的用途。
• HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS
  申请人：ATIR Holding S.A.

  公开号：US20130072479A1

  公开（公告）日：2013-03-21

  Novel heterocyclic compounds, which exhibit a dopamine receptor (preferably a D4 receptor) agonistic activity, and/or a PDE5 inhibitory activity, processes of preparing same, pharmaceutical compositions containing same and uses thereof in the treatment of sexual disorders such as decreased libido, orgasm disorder and erectile dysfunction are disclosed.

  本发明涉及一种新型杂环化合物，该化合物表现出多巴胺受体（优选为D4受体）的激动作用和/或PDE5抑制活性，以及制备该化合物的方法，含有该化合物的制药组合物以及在治疗性欲减退、性高潮障碍和勃起功能障碍等性障碍方面的应用。
• US5519023A
  申请人：——

  公开号：US5519023A

  公开（公告）日：1996-05-21
• US8349850B2
  申请人：——

  公开号：US8349850B2

  公开（公告）日：2013-01-08
• US8614319B2
  申请人：——

  公开号：US8614319B2

  公开（公告）日：2013-12-24